Efficacy of antibiotic prophylaxis against ventilator-associated pneumonia - 20/02/19
, M. Ebrahimi Monfared c, A. Jokar dSummary |
Ventilator-associated pneumonia (VAP) is one of the most important problems of intensive care units. Eighty-four neurologic patients with acute stroke (Glasgow Coma Score ≤8) were entered into a double-blind clinical trial. Patients in the intervention group received piperacillin–tazobactam 4 g/0.5 g at the time of intubation and 12 h later. The incidences of early-onset (within four days of intubation) and late-onset VAP were 9.2 and 26.9 episodes per 1000 days of mechanical ventilation in the intervention and control groups, respectively (odds ratio: 0.217; 95% confidence interval: 0.056–0.085; P = 0.028). Administration of prophylactic piperacillin–tazobactam may reduce early-onset VAP, but the benefit does not extend to late-onset VAP.
Le texte complet de cet article est disponible en PDF.Keywords : Antibiotic prophylaxis, Ventilator-associated pneumonia, Piperacillin–tazobactam
Plan
Vol 101 - N° 3
P. 272-275 - mars 2019 Retour au numéro
Article précédent
- Reduction of nosocomial bloodstream infections and nosocomial vancomycin-resistant Enterococcus faecium on an intensive care unit after introduction of antiseptic octenidine-based bathing
- S. Messler, I. Klare, F. Wappler, G. Werner, U. Ligges, S.G. Sakka, F. Mattner
- Implementation of influenza point-of-care testing and patient cohorting during a high-incidence season: a retrospective analysis of impact on infection prevention and control and clinical outcomes
- J. Youngs, B. Marshall, M. Farragher, L. Whitney, S. Glass, C. Pope, T. Planche, P. Riley, D. Carrington
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?